Japan’s Shionogi & Co. Ltd. believes its COVID-19 pill will easily garner $2 billion in annual sales if it secures U.S. approval, which the company expects to receive in late 2024, its chief executive said.
Posts
A Japanese health ministry panel on Wednesday delayed emergency approval for an oral treatment against COVID-19 that has been developed by Shionogi & Co.
